Suppr超能文献

微波消融治疗术后或消融治疗后持续性/复发性甲状旁腺功能亢进症患者的并发症。

Complications of microwave ablation in patients with persistent/recurrent hyperparathyroidism after surgical or ablative treatment.

机构信息

Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.

出版信息

Int J Hyperthermia. 2024;41(1):2308063. doi: 10.1080/02656736.2024.2308063. Epub 2024 Feb 5.

Abstract

OBJECTIVE

To evaluate the complications associated with microwave ablation (MWA) in treating persistent/recurrent hyperparathyroidism (HPT) post-surgical or ablative treatments.

MATERIALS AND METHODS

From January 2015 to December 2022, 87 persistent/recurrent HPT patients (primary HPT [PHPT]: secondary HPT [SHPT] = 13:74) who underwent MWA after surgical or ablative treatment were studied. Grouping was based on ablation order (initial vs. re-MWA), prior treatment (parathyroidectomy [PTX] vs. MWA), and etiology (PHPT vs. SHPT). The study focused on documenting and comparing treatment complications and analyzing major complication risk factors.

RESULT

Among the 87 patients, the overall complication rate was 17.6% (15/87), with major complications at 13.8% (12/87) and minor complications at 3.4% (3/87). Major complications included recurrent laryngeal nerve (RLN) palsy (12.6%) and Horner syndrome (1.1%), while minor complications were limited to hematoma (3.4%). Severe hypocalcemia noted in 21.6% of SHPT patients. No significant differences in major complication rates were observed between initial and re-MWA groups (10.7% vs. 13.8%,  = 0.455), PTX and MWA groups (12.5% vs. 15.4%,  = 0.770), or PHPT and SHPT groups (15.4% vs. 13.5%,  > 0.999). Risk factors for RLN palsy included ablation of superior and large parathyroid glands (>1.7 cm). All patients recovered spontaneously except for one with permanent RLN palsy in the PTX group (2.1%).

CONCLUSION

Complication rates for MWA post-surgical or ablative treatments were comparable to initial MWA rates. Most complications were transient, indicating MWA as a viable and safe treatment option for persistent/recurrent HPT patients.

摘要

目的

评估微波消融(MWA)治疗术后或消融治疗后持续性/复发性甲状旁腺功能亢进症(HPT)相关并发症。

材料与方法

本研究纳入 2015 年 1 月至 2022 年 12 月间 87 例接受过手术或消融治疗后行 MWA 的持续性/复发性 HPT 患者(原发性 HPT [PHPT]:继发性 HPT [SHPT]=13:74)。分组基于消融顺序(首次 vs. 再次 MWA)、既往治疗(甲状旁腺切除术 [PTX] vs. MWA)和病因(PHPT vs. SHPT)。研究重点记录和比较治疗并发症,并分析主要并发症的危险因素。

结果

87 例患者中,总并发症发生率为 17.6%(15/87),其中重大并发症发生率为 13.8%(12/87),轻微并发症发生率为 3.4%(3/87)。重大并发症包括喉返神经(RLN)麻痹(12.6%)和霍纳综合征(1.1%),而轻微并发症仅限于血肿(3.4%)。21.6%的 SHPT 患者出现严重低钙血症。首次和再次 MWA 组(10.7% vs. 13.8%,  = 0.455)、PTX 和 MWA 组(12.5% vs. 15.4%,  = 0.770)或 PHPT 和 SHPT 组(15.4% vs. 13.5%,  > 0.999)间重大并发症发生率无显著差异。RLN 麻痹的危险因素包括消融大于 1.7cm 的上极和大甲状旁腺。除了 1 例 PTX 组出现永久性 RLN 麻痹的患者外(2.1%),所有患者均自发恢复。

结论

术后或消融治疗后 MWA 的并发症发生率与首次 MWA 相当。大多数并发症是短暂的,表明 MWA 是治疗持续性/复发性 HPT 患者的可行且安全的选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验